Dr. Mark Adam Ramirez, MD

Dr. Ramirez practices at West Texas Dermatology and Skin Cancer Center in San Angelo, Texas.

Dr. Ramirez's NPI, 1639373210, was assigned on June 14, 2007. Dr. Ramirez graduated from UTMB Health in 2004. Dr. Ramirez's Texas license number on file is M7551.

Dr. Ramirez's primary practice is West Texas Dermatology and Skin Cancer Center, at 3555 Knickerbocker Rd, San Angelo, TX 76904 in Tom Green County. The practice phone is (325) 224-5981.

Dr. Ramirez's primary practice is West Texas Dermatology and Skin Cancer Center in San Angelo, Texas. Dr. Ramirez is also affiliated with Shannon Medical Center. Dmand AI also links Dr. Ramirez to 1 more physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramirez practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Ramirez's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Ramirez is board certified in dermatology by the American Board of Dermatology. Dr. Ramirez has a license on file in Texas.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Ramirez treats.

CMS data shows 8,925 Medicare services from Dr. Ramirez across 32 procedure codes in 2024, for 1,090 Medicare patients. Medicare paid $370,920 for them. Every service was in an office.

CMS counts 1,090 Medicare patients who saw Dr. Ramirez in 2024. The largest group is 65 to 74, with 525 patients. 73% of them have high blood pressure, and 73% have high cholesterol. 2% are also on Medicaid. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ramirez's median patient age at 74, with 49% women.

In 2024, Dr. Ramirez wrote 1,364 Medicare Part D claims for 579 patients. 95% of them were for generic drugs. CMS names the drug for 1,254 of them, across 21 drugs with 11 or more claims each, at $253,078 in total drug cost. In 2023, CMS named 1,072 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Ramirez for performance year 2024, reported individually. Dr. Ramirez accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,131 procedures of removal of skin lesions by Dr. Ramirez, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 2 papers to Dr. Ramirez. Dr. Ramirez's most frequent co-authors are Dayna Gwinup Diven, MD and Molly Mae Warthan, MD.

CMS Open Payments shows 18 general payments to Dr. Ramirez from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $232.

Dmand AI lists 1 award for Dr. Ramirez.

Dr. Ramirez graduated from UTMB Health in 2004. Dr. Ramirez is a member of AAD.

Dr. Ramirez is in network with 21 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.